ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 182 filers reported holding ARCUS BIOSCIENCES INC in Q1 2023. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70,005 | -11.6% | 3,900 | 0.0% | 0.07% | -10.8% |
| Q2 2023 | $79,209 | +11.3% | 3,900 | 0.0% | 0.07% | +7.2% |
| Q1 2023 | $71,136 | -11.8% | 3,900 | 0.0% | 0.07% | -9.2% |
| Q4 2022 | $80,652 | -20.9% | 3,900 | 0.0% | 0.08% | -27.6% |
| Q3 2022 | $102,000 | -93.7% | 3,900 | -93.9% | 0.10% | -92.1% |
| Q2 2022 | $1,622,000 | -19.7% | 64,000 | 0.0% | 1.33% | -20.7% |
| Q1 2022 | $2,020,000 | -22.0% | 64,000 | 0.0% | 1.68% | -17.8% |
| Q4 2021 | $2,590,000 | +48.5% | 64,000 | +28.0% | 2.04% | +54.3% |
| Q3 2021 | $1,744,000 | -36.5% | 50,000 | -50.0% | 1.32% | -36.1% |
| Q2 2021 | $2,746,000 | – | 100,000 | – | 2.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
| Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
| Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
| DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
| PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
| Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
| Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
| Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |